Stockscreener 앱 받기
53.84
0.19%
-0.10
시장 영업 전:
54.40
0.56
+1.04%
전일 마감가:
$53.94
열려 있는:
$54.225
하루 거래량:
3.03M
Relative Volume:
0.58
시가총액:
$107.65B
수익:
$43.11B
순이익/손실:
$8.29B
주가수익비율:
14.70
EPS:
3.6638
순현금흐름:
$5.71B
1주 성능:
+3.86%
1개월 성능:
-8.95%
6개월 성능:
+35.11%
1년 성능:
+39.77%
1일 변동 폭
$53.79
$54.75
1주일 범위
$51.71
$54.98
52주 변동 폭
$32.38
$61.70
글락소스미스클라인 ADR Stock (GSK) Company Profile
Compare GSK vs LLY, JNJ, ABBV, MRK, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
53.84 | 107.65B | 43.11B | 8.29B | 5.71B | 3.6638 |
LLY
Lilly Eli Co
|
878.24 | 784.58B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.45 | 579.15B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
209.40 | 370.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.63 | 295.77B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
188.42 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
글락소스미스클라인 ADR Stock (GSK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 개시 | Citigroup | Neutral |
| 2026-01-06 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-11-25 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-06-03 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-04-15 | 개시 | Exane BNP Paribas | Neutral |
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-11-15 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-11-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-10-31 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-07-08 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-05-30 | 개시 | Goldman | Neutral |
| 2024-03-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-02-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2024-01-03 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-03-17 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-02-27 | 재개 | Goldman | Buy |
| 2023-01-03 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-12-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-11 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-09-15 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-21 | 재개 | Citigroup | Neutral |
| 2022-02-11 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2021-06-24 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2021-03-23 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | 개시 | Deutsche Bank | Hold |
| 2020-11-02 | 업그레이드 | Liberum | Hold → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-02-12 | 다운그레이드 | Shore Capital | Hold → Sell |
| 2020-01-16 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2019-12-02 | 개시 | SVB Leerink | Outperform |
| 2019-11-21 | 업그레이드 | UBS | Neutral → Buy |
| 2019-10-11 | 업그레이드 | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | 재개 | Citigroup | Neutral |
| 2019-09-03 | 업그레이드 | Societe Generale | Sell → Buy |
| 2019-08-13 | 재개 | JP Morgan | Neutral |
| 2019-06-17 | 재개 | Morgan Stanley | Underweight |
| 2019-03-08 | 다운그레이드 | Shore Capital | Buy → Hold |
| 2019-02-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-01-14 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | 재개 | Jefferies | Buy |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-08-30 | 다운그레이드 | Liberum | Buy → Hold |
| 2018-04-04 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | 업그레이드 | Kepler | Reduce → Hold |
모두보기
글락소스미스클라인 ADR 주식(GSK)의 최신 뉴스
Sitryx to participate in upcoming April investor conferences - GlobeNewswire Inc.
GSK Fundamental Analysis & Valuation | Fair Value & Financial Strength | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
GSK plc (ADR) stock surges on FDA approval for Lynavoy as pipeline momentum builds for 2026 - AD HOC NEWS
GSK Stock Price, Quote & Chart | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
GSK's Q4 earnings & sales beat estimates, stock up on '26 outlook - MSN
GSK PLC Sponsored ADR (NYSE:GSK) Short Interest Update - MarketBeat
FDA Broadens Access To GSK's Respiratory Syncytial Virus Shot For Younger High-Risk Adults - Sahm
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Sold by Quantbot Technologies LP - MarketBeat
GSK (NYSE: GSK) files 2025 Form 20-F with audited 2025 financial statements - Stock Titan
Price Over Earnings Overview: GSK - Sahm
GlaxoSmithKline Pharma: Can India’s GSK Arm Still Reward US Investors? - AD HOC NEWS
GSK PLC Sponsored ADR $GSK Shares Sold by Kahn Brothers Group Inc. - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Short Interest Down 26.3% in February - MarketBeat
CapEx per share of GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs – BCBA:GSKD - TradingView
Fisher Asset Management LLC Purchases 889,210 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
Antibiotics Market - GlobeNewswire Inc.
GSK Expands Pipeline With $950 Million Pulmonary Hypertension Power Play - Sahm
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus - Finviz
GSK (GSK) Announces 75.6% Vaccine Effectiveness for Arexvy in Real-World RSV Study - Finviz
Moderna Stock Jumps After FDA Reverses Course on Flu Shot - TradingView
GlaxoSmithKline Pharma: Quiet India Move, Big Signal for U.S. Portfolios? - AD HOC NEWS
GSK plc (GSK) Q4 Results Topped Forecasts as Specialty Medicines Jump 17% - Finviz
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of “Reduce” from Brokerages - Defense World
Is GSK PLC Gaining or Losing Market Support? - Sahm
BI Asset Management Fondsmaeglerselskab A S Reduces Stake in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK Gets EU Approval for Expanded Use of Nucala in COPD - Finviz
GSK PLC Sponsored ADR (NYSE:GSK) Declares Dividend Increase$0.49 Per Share - MarketBeat
ANALYSIS-Novo Nordisk risks weight-loss price war as discount pressures deepen - Sahm
3 International Stocks to Buy for 2026 - Morningstar
GSK Set up for Steady Long-Term Growth as Portfolio and Pipeline Develop - Morningstar
GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook - TradingView
10 best global blue-chip stocks to buy for the long term - Morningstar
GSK plc (ADR): Quiet Rally, Loud Expectations – Is the Stock Finally Escaping Its Legal Overhang? - AD HOC NEWS
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
글락소스미스클라인 ADR (GSK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.92%
2.74%
자본화:
|
볼륨(24시간):